NCT04465214Completed
Mobile Sensor Technologies to Assess General Symptomology of People With Cancer
A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
Background: Many digital devices, such as smartphones and activity monitors, have sensors to collect and track health data. Researchers believe these devices may be able to transform the quality of clinical research and healthcare. They believe they may be able to help assess the symptoms, response to therapy, and quality of life of people with cancer. Objective: To collect data from people with cancer using an Apple iPhone alone or together with an Apple Watch in order to assess their symptoms and activity levels. Eligibility: People ages 18 years and over who have cancer and receiving treatment for their cancer in another NIH protocol Design: Participants will be screened with their medical records. Participants will have a baseline visit. They will have visits every 2 4 weeks based on the treatment protocol in which they are co-enrolled. Then they will have a follow-up visit 4 months after the baseline visit. Visits include: Medical history Physical exam Karnofsky Performance Scale/Eastern Cooperative Oncology Group performance status to see how their disease affects daily activities The study team will use an iPhone to collect data. This includes a 6-minute walk test and tests of hearing, reaction time, and cognitive status. Questionnaires If participants have an iPhone, an Apple Watch will be provided to them after training at the baseline visit. Continuous measurement of their activity will be recorded by the watch between 2 visits. They will wear the watch while they are on study. They will wear the watch while it is not being charged. They should charge the watch at night time. They will have the watch for 4 months.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 49 (actual)
- First submitted
- 9 Jul 2020
- Start date
- 23 Nov 2020
- Primary completion date
- 10 Apr 2024
- Lead sponsor
- National Cancer Institute (NCI)
- Diseases
- Prostate cancer, Lung cancer, Colorectal cancer
- NCT number
- NCT04465214
What you commit to
- Study type: Observational
- Participants enrolled: 49
- From 23 Nov 2020 to the primary completion date, 10 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known current alcohol or drug abuse.
- Cancer survivors who are not actively receiving treatment.
Other illness
- Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Resting heart rate at screening, higher than 120 beats per minute.
Other
- Active central nervous system (CNS) metastases.
- Current marijuana use, including for medicinal purposes.
- Color blindness to any of the following colors: green, yellow, and/or red.
- Legal incapacity or limited legal capacity.
- Non-English speaking subjects.
- Systolic blood pressure at screening, higher than 180 mmHg.
- Diastolic blood pressure at screening, higher than 100 mmHg.
Criteria the registry did not label
- INCLUSION CRITERIA:
- Signed written informed consent.
- Male or female subjects aged greater than or equal to 18 years.
- A cancer diagnosis.
- Participant should be under active treatment for cancer on a protocol at NIH.
Age in the registry: 18 years to 120 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Institutes of Health Clinical Center Coordinator of this site? Confirm its status | Bethesda | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.